论文部分内容阅读
目的 观察降纤酶治疗急性脑梗死的临床疗效。方法 用国产双盲编号的降纤酶静滴治疗发病2 4 h内的急性脑梗死患者 65例 (治疗组 31例、对照组 34例 ) ,并同时于治疗前、后进行神经功能缺损评分及检测血浆纤维蛋白原 ( FG)、凝血酶原时间 ( PT)、凝血酶原活动度 ( PA)。结果 神经功能缺损评分显著进步率 ,降纤酶治疗组 74 .2 % ,明显优于对照组的 2 9.2 % ,两组比较有显著性差异 ( P <0 .0 0 1 ) ;治疗组 FG降低明显优于对照组 ( P <0 .0 0 1 )。结论 降纤酶治疗急性脑梗死有效 ,与降低血浆纤维蛋白原明显相关。
Objective To observe the clinical efficacy of defibrase in the treatment of acute cerebral infarction. Methods 65 patients with acute cerebral infarction within 24 hours of onset (31 in the treatment group and 34 in the control group) were treated with domestic double-blind numbering defibrase and the neurological deficit score Plasma fibrinogen (FG), prothrombin time (PT) and prothrombin activity (PA) were measured. Results The neurological deficit score was significantly improved, with 74.2% of the defibrase-treated group significantly better than that of the control group (9.22%), with significant difference between the two groups (P <0.01) Obviously superior to the control group (P <0.001). Conclusion Defibrase is effective in the treatment of acute cerebral infarction and is obviously related to the reduction of plasma fibrinogen.